Shares of Illumina (NASDAQ: ILMN), a leading provider of DNA sequencing technologies, surged 5.11% in pre-market trading on Tuesday. The stock rally came after the company reported preliminary financial results for the fourth quarter and full year 2024, along with a positive outlook for the upcoming fiscal year 2025.
According to the preliminary results, Illumina recorded revenue of approximately $1.1 billion for the fourth quarter of 2024, representing a 1% increase compared to the same period in the previous year. For the full fiscal year 2024, the company reported revenue of around $4.33 billion, down 2% from 2023.
Illumina's non-GAAP earnings per share (EPS) for the fourth quarter of 2024 are expected to be in the range of $0.91 to $0.93, while the full-year 2024 non-GAAP EPS is projected to be between $4.12 and $4.14. The company's cash flow from operations for 2024 stood at approximately $1.21 billion, with free cash flow reaching around $1.07 billion.
Looking ahead to fiscal year 2025, Illumina provided an optimistic outlook, forecasting low single-digit revenue growth on a constant currency basis. The company expects reported revenue to range between $4.28 billion and $4.4 billion, with a non-GAAP operating margin of approximately 23%. Additionally, Illumina anticipates its non-GAAP diluted EPS to grow by approximately 10% in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.